Unfortunately, Lineage's IPO price marked the high-water mark for the shares. They've gone on to lose more than half their ...

Truist lowered the firm’s price target on Lineage (LINE) to $40 from $53 and keeps a Buy rating on the shares. The firm, which is lowering its ...

CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, ...

Lineage trades at a NAV discount with recovery potential, a 6.1% yield at 64% payout, expanding scale, and catalysts from rates. Read why LINE stock is a buy.

BofA Securities analyst Jeffrey Spector downgraded Lineage Inc (NASDAQ:LINE) to Neutral from Buy on Tuesday and lowered the price forecast from $70.00 to $49.00. The analyst downgraded LINE and ...

Methods for tracing lineage can be divided into two groups. Prospective methods trace lineage forwards from the application of an experimentally delivered marker, and retrospective methods trace ...